Background and Objectives: While trying to optimize the dialysis clearances of protein-bound uremic toxins (PBUTs), their percentage protein binding (% PB) is an important parameter. We evaluated the effects of ionic strength, pH change and chemical displacers on the dissociation of PBUTs from albumin in vitro. Methods: PBUTs, such as 3-Carboxy-4-methyl-5-propyl-2-furan-propanoic acid (CMPF), p-cresylsulfate (PCS), indoxyl sulfate (IS) and indole-3-acetic acid (IAA), were spiked with human serum albumin (HSA) solution prepared with different Nacl concentrations and pH values or in the presence of a series of chemical displacers. Ultrafiltration was performed to separate the free and bound fractions, and the % PB of each PBUT was calculated. Results: For all 4 compounds, their % PB decreased with increasing ionic strength, while only slight changes occurred when the pH of the test solution increased from pH 6.0 to pH 8.5; PCS, IS and 3-IAA were relatively easily dissociated from albumin by drug displacement, while CMPF was released from HSA by all studied drugs with difficulty; the PB % for CMPF, PCS, IS and 3-IAA decreased most remarkably in the presence of free fatty acids, such as oleic acid (41.73% for CMPF, 29.9% for PCS, 23.22% for IS, and 20.34% for 3-IAA) and linoleic acid (43.12% for CMPF, 16.65% for PCS, 29.99% for IS, and 16.29% for 3-IAA). Conclusion: The protein binding of PBUTs can be decreased by higher ionic strength, increased pH and the presence of some chemical displacers, including free fatty acids. Effective dialytic removal of PBUTs may be achieved by applying these methods jointly to blood-purification techniques.

Keywords:
Protein-bound uremic toxin, Ionic strength, pH, Chemical displacers, Percentage protein binding
1.
Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jörres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W; European Uremic Toxin Work Group (EUTox): Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934–1943.
2.
Meijers BK, Bammens B, Verbeke K, Evenepoel P: A review of albumin binding in CKD. Am J Kidney Dis 2008; 51: 839–850.
3.
Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G: The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol 2014; 25: 1897–1907.
4.
Leong SC, Sirich TL: Indoxyl sulfate-review of toxicity and therapeutic strategies. Toxins (Basel) 2016; 8:E358.
5.
Gryp T, Vanholder R, Vaneechoutte M, Glorieux G: p-cresyl sulfate. Toxins (Basel) 2017; 9:E52.
6.
Dou L, Sallée M, Cerini C, Poitevin S, Gondouin B, Jourde-Chiche N, Fallague K, Brunet P, Calaf R, Dussol B, Mallet B, Dignat-George F, Burtey S: The cardiovascular effect of the uremic solute indole-3 acetic acid. J Am Soc Nephrol 2015; 26: 876–887.
7.
Martinez AW, Recht NS, Hostetter TH, Meyer TW: Removal of P-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005; 16: 3430–3436.
8.
Niwa T: Removal of protein-bound uraemic toxins by haemodialysis. Blood Purif 2013; 35 (suppl 2): 20–25.
9.
Sakai T, Takadate A, Otagiri M: Characterization of binding site of uremic toxins on human serum albumin. Biol Pharm Bull 1995; 18: 1755–1761.
10.
Sakai T, Yamasaki K, Sako T, Kragh-Hansen U, Suenaga A, Otagiri M: Interaction mechanism between indoxyl sulfate, a typical uremic toxin bound to site II, and ligands bound to site I of human serum albumin. Pharm Res 2001; 18: 520–524.
11.
Watanabe H, Noguchi T, Miyamoto Y, Kadowaki D, Kotani S, Nakajima M, Miyamura S, Ishima Y, Otagiri M, Maruyama T: Interaction between two sulfate-conjugated uremic toxins, p-cresyl sulfate and indoxyl sulfate, during binding with human serum albumin. Drug Metab Dispos 2012; 40: 1423–1428.
12.
Viaene L, Annaert P, de Loor H, Poesen R, Evenepoel P, Meijers B: Albumin is the main plasma binding protein for indoxyl sulfate and p-cresyl sulfate. Biopharm Drug Dispos 2013; 34: 165–175.
13.
Deltombe O, de Loor H, Glorieux G, Dhondt A, Van Biesen W, Meijers B, Eloot S: Exploring binding characteristics and the related competition of different protein-bound uremic toxins. Biochimie 2017; 139: 20–26.
14.
Meyer TW, Leeper EC, Bartlett DW, Depner TA, Lit YZ, Robertson CR, Hostetter TH: Increasing dialysate flow and dialyzer mass transfer area coefficient to increase the clearance of protein-bound solutes. J Am Soc Nephrol 2004; 15: 1927–1935.
15.
Böhringer F, Jankowski V, Gajjala PR, Zidek W, Jankowski J: Release of uremic retention solutes from protein binding by hypertonic predilution hemodiafiltration. ASAIO J 2015; 6: 55–60.
16.
Krieter DH, Devine E, Körner T, Rüth M, Wanner C, Raine M, Jankowski J, Lemke HD: Haemodiafiltration at increased plasma ionic strength for improved protein-bound toxin removal. Acta Physiol (Oxf) 2017; 219: 510–520.
17.
Tao X, Thijssen S, Kotanko P, Ho CH, Henrie M, Stroup E, Handelman G: Improved dialytic removal of protein-bound uraemic toxins with use of albumin binding competitors: an in vitro human whole blood study. Sci Rep 2016; 6: 23389.
18.
Mabuchi H, Nakahashi H, Hamajima T, Aikawa I, Oka T: The effect of renal transplantation on a major endogenous ligand retained in uremic serum. Am J Kidney Dis 1989; 13: 49–54.
19.
Florens N, Yi D, Juillard L, Soulage CO: Using binding competitors of albumin to promote the removal of protein-bound uremic toxins in hemodialysis: hope or pipe dream? Biochimie 2018; 144: 1–8.
20.
Shafi T, Sirich TL, Meyer TW, Hostetter TH, Plummer NS, Hwang S, Melamed ML, Banerjee T, Coresh J, Powe NR: Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes. Kidney Int 2017; 92: 1484–1492.
21.
Evenepoel P, Glorieux G, Meijers B: p-cresol sulfate and indoxyl sulfate: some clouds are gathering in the uremic toxin sky. Kidney Int 2017; 92: 1323–1324.
22.
Koppe L, Poitout V: CMPF: A biomarker for type 2 diabetes mellitus progression? Trends Endocrinol Metab 2016; 27: 439–440.
23.
Costigan MG, Callaghan CA, Lindup WE: Hypothesis: is accumulation of a furan -dicarboxylic acid (3-carboxy-4- methyl-5-propyl-2-furanpropanoic acid) related to the neurological abnormalities in patients with renal failure? Nephron 1996; 73: 169–173.
24.
Lim CF, Docter R, Krenning EP, van Toor H, Bernard B, de Jong M, Hennemann G: Transport of thyroxine into cultured hepatocytes: effects of mild non-thyroidal illness and calorie restriction in obese subjects. Clin Endocrinol (Oxf) 1994; 40: 79–85.
25.
Prentice KJ, Luu L, Allister EM, Liu Y, Jun LS, Sloop KW, Hardy AB, Wei L, Jia W, Fantus IG, Sweet DH, Sweeney G, Retnakaran R, Dai FF, Wheeler MB: The furan fatty acid metabolite CMPF is elevated in diabetes and induces β cell dysfunction. Cell Metab 2014; 19: 653–666.
26.
Meyer TW, Walther JL, Pagtalunan ME, Martinez AW, Torkamani A, Fong PD, Recht NS, Robertson CR, Hostetter TH: The clearance of protein-bound solutes by hemofiltration and hemodiafiltration. Kidney Int. 2005; 68: 867–877.
27.
Deltombe O, Dhondt A, Biesen WV, Glorieux G, Eloot S: Effect of sample temperature, pH, and matrix on the percentage protein binding of protein-bound uraemic toxins. Anal. Methods 2017; 9: 1935–1940.
28.
Etinger A, Kumar, Ackley W, Soiefer L, Chun J, Singh P, Grossman E, Matalon A, Holzman RS, Meijers B, Lowenstein J: The effect of isohydric hemodialysis on the binding and removal of uremic retention solutes. PLoS One 2018; 13:e0192770.
29.
Al-Chalabi A, Matevossian E, von Thaden A, Schreiber C, Radermacher P, Huber W, Perez Ruiz de Garibay A, Kreymann B: Evaluation of an ADVanced Organ Support (ADVOS) system in a two-hit porcine model of liver failure plus endotoxemia. Intensive Care Med Exp 2017; 5: 31.
30.
Yamasaki K, Chuang VT, Maruyama T, Otagiri M: Albumin-drug interaction and its clinical implication. Biochim Biophys Acta 2013; 1830: 5435–5443.
31.
Takamura N, Maruyama T, Chosa E, Kawai K, Tsutsumi Y, Uryu Y, Yamasaki K, Deguchi T, Otagiri M: Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of Bucolome to restore diuretic response in nephrotic syndrome. Drug Metab Dispos 2005; 33: 596–602.
32.
Setoguchi N, Takamura N, Fujita K, Ogata K, Tokunaga J, Nishio T, Chosa E, Arimori K, Kawai K, Yamamoto R: A diclofenac suppository-nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis. Biopharm Drug Dispos 2013; 34: 125–136.
33.
Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P: Human serum albumin: from bench to bedside. Mol Aspects Med 2012; 33: 209–290.
34.
Wolever TM, Bentum-Williams A, Jenkins DJ: Physiological modulation of plasma free fatty acid concentrations by diet. Metabolic implications in nondiabetic subjects. Diabetes Care 1995; 18: 962–970.
35.
De Smet R, Van Kaer J, Liebich H, Lesaffer G, Verstraete A, Dhondt A, Duym P, Lameire N, Vanholder R: Heparin-induced release of protein-bound solutes during hemodialysis is an in vitro artifact. Clin Chem 2001; 47: 901–909.
36.
Spector AA: Fatty acid binding to plasma albumin. J Lipid Res 1975; 16: 165–179.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.